Management

Dr. Julie Cherrington, Ph.D.President and Chief Executive Officer

Dr. Julie M. Cherrington, Ph.D. is President and CEO of Zenith Epigenetics Corp. Dr. Cherrington is a life science executive with extensive experience bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.

Julie joined Zenith Epigenetics as President and CEO in July 2014. From 2009 to 2014, Julie was President and CEO of Pathway Therapeutics, a clinical stage company advancing targeted kinase inhibitors for the treatment of cancer, autoimmune and respiratory indications. Prior to joining Pathway, she served as President of Phenomix Corporation where she led diabetes and HCV research and development, and played a leadership role in financing and business development. Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pfizer company. Julie began her career at Gilead Sciences where she held a range of positions of increasing responsibility.

She has served on the Boards of Directors of Chemgenex, Progen and Xenome. She is currently a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at UC San Francisco, UC Davis, Stanford and BayBio.

Dr. Norman C.W. Wong, M.D., FRCPChief Scientific Officer

Norman Wong is Chief Scientific Officer at Zenith Epigenetics. Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus.  These topics of interest involved studies of chromatin structure, gene regulation and transcription factors which are major components of epigenetics.  His clinical interest encompasses patients with thyroid disease including thyroid cancer or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression using inhibition of BET-proteins that play important roles in epigenetics.

Dr. Wong keeps active in the academic community by participating in speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

A. Brad Cann, CAChief Financial Officer

Brad has more than 18 years of financial and business experience. Between 2004 and 2009, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust (REIT), a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions. 

Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.

Dr. Henrik C. Hansen, Ph.D.Vice President of Intellectual Property & Technology Development

Dr. Hansen is the VP of Intellectual Property & Technology Development at Zenith. Henrik is responsible for the intellectual property portfolio, and he assumes a leading role in the implementation of corporate objectives by interfacing with all parts of the corporation; monitors resource needs and ensures that appropriate resources are available and aligned with corporate goals. He provides insight to achieve the right balance between science, business, and financial objectives, by applying a strong understanding of all aspects of the corporation.

Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry, carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under Current Good Manufacturing Practices (cGMPs) for clinical use.

Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as an inventor of 9 patent families.

Dr. Ravi Jahagirdar, DVM, MS.Senior Director of Pharmacology

Ravi is the Senior Director of Pharmacology. Ravi has a strong background in animal, lipid/lipoprotein physiology and manages all discovery in vivo pharmacology related to autoimmune and oncology programs at Zenith.

Ravi has over 17 years of experience from both academia and industry in in-vivo pharmacology, animal physiology, drug discovery, early toxicology and pharmacokinetic studies, basic research, assay development and high throughput screening. He has been successful in recruiting scientists, building departments and managing projects from early discovery to pre-clinical development and business collaborations. 

Ravi completed his Doctor of Veterinary Medicine in Bangalore, MS in Molecular Biology/Microbiology at Health Sciences Center (MUN, Newfoundland) and followed with basic research on understanding toxin secretion in gram negative bacteria in relationship to ABC proteins during his tenure at University of Regina. Ravi’s research has been published in many peer reviewed journals and has co-authored a text book chapter and has numerous abstract presentations.  

Dr. Kevin G. McLure, Ph.D.Senior Director of Translational Biology

Dr. McLure oversees the biology research group as the Senior Director of Translational Biology. Kevin’s responsibility for biology research encompasses mechanism of action, lead discovery and biomarkers in oncology, autoimmune and other programs. Kevin directs internal programs and manages external research collaborations. He has more than 15 years of experience in academia and industry, basic research and drug discovery. His areas of expertise include chromatin structure and transcriptional regulation, molecular oncology and basic cancer research, biochemistry, assay development & validation.

Kevin completed his PhD in Molecular Oncology at the University of Calgary with a focus on cancer therapeutic and metabolic regulation of p53 and chromatin in DNA damage responses at St. Jude Children’s Research Hospital (Memphis, TN). He has authored and co-authored more than 25 publications and meeting abstracts and is listed as an inventor of 5 patents.